Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dermal Advantage is a brand of high-potency topical urea formulations, typically containing 40% or 50% urea, used as a potent keratolytic agent. It is designed to treat hyperkeratotic skin conditions and dystrophic nail disorders by increasing the water-binding capacity of the stratum corneum and facilitating the denaturation and solubilization of proteins like keratin. This process promotes the debridement of necrotic tissue and the softening of thickened skin or nails, making it effective for conditions such as psoriasis, xerosis, ichthyosis, and the non-surgical removal of damaged nails. It is generally marketed as a professional-grade or prescription-strength topical treatment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dermal Advantage.